Membrane-independent CD59 Gene Therapy for AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) are inadequate, particularly for dry AMD, as they do not halt disease progression, and there is a need for methods to diagnose, assay potential therapeutic agents, and treat AMD effectively.
Innovation Solution
A pharmaceutical composition comprising a nucleotide sequence encoding a membrane-independent CD59 protein, formulated with a pharmaceutically acceptable buffer, is administered to treat AMD, using vectors like adenovirus or adeno-associated virus for ocular delivery, which expresses a recombinant membrane-independent CD59 protein that inhibits glycosyl phosphatidyl inositol anchoring, allowing for local secretion and reducing complement activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If current treatments (laser surgery, photodynamic therapy, injections) are used for wet AMD, then progression of the disease is slowed, but the treatments do not cure wet AMD and require repeated interventions
Solution Approach 1:
The patent introduces a gene therapy approach where a nucleic acid sequence encoding a complement regulatory protein is delivered to ocular tissues before complement-mediated damage occurs. This preliminary genetic intervention enables the tissue to produce its own protective protein, creating long-term immunity against complement attacks without requiring repeated treatments.
Solution Approach 2:
The gene therapy enables ocular tissues to self-produce the complement regulatory protein through endogenous expression of the introduced nucleic acid sequence. The tissue serves itself by continuously producing the protective protein, eliminating the need for external repeated interventions like injections or surgeries.
2Ease of manufacture
If no treatment is used for advanced stage dry AMD, then there is no known form of treatment, but vision loss is inevitable
Solution Approach 1:
The patent applies gene therapy to deliver a nucleic acid sequence encoding a complement regulatory protein to ocular tissues affected by dry AMD. This preliminary genetic intervention establishes continuous protein production that protects against complement-mediated damage, providing a treatment option where previously none existed.
Solution Approach 2:
The introduced nucleic acid sequence acts as an intermediary that enables the production of complement regulatory protein, which in turn mediates protection against complement attacks. This intermediary genetic material bridges the gap between the administered therapy and the protective effect against vision loss.
3Reliability
If membrane-bound CD59 is used, then complement activity is regulated, but the protein requires membrane anchoring via GPI linkage which complicates delivery and expression
Solution Approach 1:
The patent extracts the complement regulatory domain from the membrane-bound CD59 protein and removes the complex GPI anchoring sequence. This creates a simplified soluble form of the protein that retains complement regulatory function without requiring membrane attachment, facilitating easier delivery and expression through gene therapy.
Solution Approach 2:
The patent changes the physical state of the CD59 protein from membrane-bound to soluble by modifying its structure. This parameter change from anchored to unanchored form simplifies the protein's delivery and expression while maintaining its complement regulatory efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces complement activity and MAC deposition, providing a potential treatment for both wet and dry forms of AMD by inhibiting choroidal neovascularization and protecting ocular tissues from human complement-mediated damage.
Implementation Method 1
a nucleotide sequence encoding a membrane-independent CD59 protein... that inhibits glycosyl phosphatidyl inositol anchoring... reducing complement activity
Data Source
AI summary
Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.